Consumer Health Cancer / Oncology
Japan Approves Novocure’s Optune Lua for Concurrent Use with PD-1/PD-L1 Inhibitors in Advanced NSCLC
Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...
September 17, 2025 | News
Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer
Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...
September 16, 2025 | News
Biostar Pharma Doses First Patients in Two Global Phase II/III Trials of Oral Utidelone Capsule for Gastric and Ovarian Cancers
Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biolo...
September 16, 2025 | News
Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...
September 12, 2025 | News
Siemens Healthineers–YouGov Survey Reveals Fragmented Cancer Care Pathway in Southeast Asia, Underscoring Need for Integrated Solutions
YouGov survey finds strong belief in value of early detection (78%) but low screening uptake (26%) 80% of respondents aware post-treatment care exists...
September 10, 2025 | Report
XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours
XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...
September 10, 2025 | News
AstraZeneca’s FLAURA2 Trial Confirms TAGRISSO Plus Chemotherapy Extends Survival in EGFR-Mutated Lung Cancer
FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...
September 08, 2025 | News
Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...
September 08, 2025 | News
FDA Approves Henlius and Organon’s Denosumab Biosimilars BILDYOS and BILPREVDA for All US Indications
Shanghai Henlius Biotech, Inc. and Organon announced that the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) inject...
September 04, 2025 | News
China’s Akeso Completes Phase III Enrollment for Ivonescimab in Advanced Biliary Tract Cancer
Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...
September 03, 2025 | News
Lunit Secures Milestone European Deployment in Spain’s Valencian Community for AI-Powered Breast Cancer Screening
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening Lunit , a leading provider o...
September 03, 2025 | News
Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability
Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...
September 01, 2025 | Company results
ACROBiosystems and South Korea’s DAAN Biotherapeutics Sign Strategic MOU to Advance Precision Immuno-Oncology
ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced tha...
August 29, 2025 | News
China’s D3 Bio Secures FDA Breakthrough and Orphan Drug Designations for KRAS G12C Inhibitor D3S-001
Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cel...
August 29, 2025 | News
Most Read
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
